Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027
Covered in this story
Call it yourself
No calls on $PALI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Palisade Bio →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.